Infectious Diseases in Critical Care Medicine

(ff) #1

  1. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to
    Staphylococcus aureus, 2003–2004 influenza season. Emerg Infect Dis 2006; 12:894–899.

  2. Roberts JC, Gulino SP, Peak KK, et al. Fatal necrotizing pneumonia due to a Panton-Valentine
    leukocidin positive community-associated methicillin-sensitiveStaphylococcus aureusand Influenza
    co-infection: a case report. Ann Clin Microbiol Antimicrob 2008; 7:5.

  3. Nguyen ET, Kanne JP, Hoang LM, et al. Community-acquired methicillin-resistantStaphylococcus
    aureuspneumonia: radiographic and computed tomography findings. J Thorac Imaging 2008;
    23:13–19.

  4. Sakaguchi M, Shime N, Fujita N, et al. Current problems in the diagnosis and treatment of hospital-
    acquired methicillin-resistantStaphylococcus aureuspneumonia. J Anesth 2008; 22:125–130.

  5. Cunha BA.S. aureusnosocomial pneumonia: clinical aspects. Infect Dis Practice 2007; 31:557–560.

  6. Vayalumkal JV, Whittingham H, Vanderkooi O, et al. Necrotizing pneumonia and septic shock:
    suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM 2007;
    9:300–303.

  7. Olsen RJ, Burns KM, Chen L, et al. Severe necrotizing fasciitis in a human immunodeficiency
    virus-positive patient caused by methicillin-resistantStaphylococcus aureus. J Clin Microbiol 2008;
    46:1144–1147.

  8. Young LM, Price CS. Community-acquired methicillin-resistantStaphylococcus aureusemerging as an
    important cause of necrotizing fasciitis. Surg Infect 2008; 9:469–474.

  9. Lee TC, Carrick MM, Scott BG, et al. Incidence and clinical characteristics of methicillin-resistant
    Staphylococcus aureus necrotizing fasciitis in a large urban hospital. Am J Surg 2007; 194:809–812.

  10. Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due
    to methicillin-resistant and methicillin-susceptible Staphylococcus aureus.InfectControlHosp
    Epidemiol 2007; 28:273–279.

  11. Wang JL, Chen SY, Wang JT, et al. Comparison of both clinical features and mortality risk associated
    with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and
    methicillin susceptibleStaphylococcus aureus. Clin Infect Dis 2008; 46:799–806.

  12. Haessler S, Mackenzie T, Kirkland KB. Long-term outcomes following with methicillin-resistant or
    methicillin-susceptibleStaphylococcus aureus. J Hosp Infect 2008; 69:39–45.

  13. Cunha BA. Newer uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin b,
    doxycycline and minocycline revisited. Med Clin North Am 2006; 90:1089–1107.

  14. Cunha BA. Oral antibiotics to treat MRSA infections. J Hosp Infect 2005; 60:88–90.

  15. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am 2006;
    90:1197–2222.

  16. Martagon-Villami J, Brown RB. IV vs PO antibiotics: who really needs parenteral antibiotics. Antibiot
    Clin 2007; 11:429–431.

  17. Kucers A, Crowe SM, Grayson ML, et al. The Use of Antibiotics: A Clinical Review of Antibacterial,
    Antifungal and Antiviral Drugs. 5th ed. Oxford: Butterworth-Heinemann, 1997.

  18. Burns CA. Long-term use of daptomycin for MRSA osteomyelitis and joint infection. Scand J Infect
    Dis 2008; 40:183–186.

  19. Cunha BA, Krol V, Kodali V. Methicillin-resistantStaphylococcus aureus(MRSA) mitral valve acute
    bacterial endocarditis (ABE) in a patient with job’s syndrome (hyperimmunoglobulin E syndrome)
    successfully treated with linezolid and high dose daptomycin. Heart Lung 2008; 37:72–75.

  20. Daver NG, Shelburne SA, Atmar RL, et al. Oral step-down therapy is comparable to intravenous
    therapy forStaphylococcus aureusosteomyelitis. J Infect 2007; 54:539–544.

  21. Davis SL, McKinnon PS, Hall LM, et al. Daptomycin versus vancomycin for complicated skin and skin
    structure infections: clinical and economic outcomes. Pharmacotherapy 2007; 27:1611–1618.

  22. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin
    Microbiol Infect 2008; 14:3–9.

  23. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections
    caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007;
    60:1361–1369.

  24. Mergenhagen KA, Pasko MT. Daptomycin use after vancomycin -induced neutropenia in a patient
    with left-sided endocarditis. Ann Pharmacother 2007; 41:1531–1535.

  25. Mohan S, McDermott BP, Cunha BA. Methicillin-resistantStaphylococcus aureus(MRSA) prosthetic
    valve endocarditis (PVE) with paravalvular abscess treated with daptomycin. Heart Lung 2005;
    34:69–71.

  26. Moreillon P. New and emerging treatment ofStaphylococcus aureusinfections in the hospital setting.
    Clin Microbiol Infect 2008; 14:32–41.

  27. Murthy MH, Olson ME, Wickert RW, et al. Daptomycin non-susceptible methicilin-resistant
    Staphylococcus aureusUSA 300 isolate. J Med Microbiol 2008; 57:1036–1038.


510 Cunha

Free download pdf